Clinical outcomes of patients with combined idiopathic pulmonary fibrosis and emphysema in the IPF-PRO Registry

Please click the link below to download a plain language summary of the key findings of this manuscript.

Header - Navigation Icon

The IPF‑PRO/ILD‑PRO™ Registry is funded by Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) and co‑ordinated by the Duke Clinical Research Institute (DCRI). The authors meet criteria for authorship as recommended by the International Committee of Medical Journal Editors (ICMJE). The authors did not receive payment for development of this plain language summary or the article on which it is based. Writing support was provided by Julie Fleming and Wendy Morris of Fleishman‑Hillard, London, UK, which was contracted and funded by BIPI. Boehringer Ingelheim was given the opportunity to review the article and plain language summary for medical and scientific accuracy as well as intellectual property considerations.